Status
Acquired by Genentech on July 1, 2014
Headquarters:
San Diego, CA
Description:
Seragon Pharmaceuticals develops small-molecule drugs for the treatment of estrogen receptor dependent breast cancer.
Categories:
Biotechnology
Website:
http://seragonpharm.com

Company Details

Update
Founded:
2013
Contact:
Employees:
1 in CrunchBase

Seragon Pharmaceuticals' orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. SERDs are estrogen receptor antagonists that also induce a conformational change that results in the degradation of the receptor. Seragon has identified multiple SERDs that have pharmacokinetic profiles sufficient to drive a robust therapeutic response and result in degradation of the receptor and anti-tumor activity. The novel profile of these potent, orally bioavailable, nonsteroidal agents may result in greater efficacy and response rates in patients with hormone-refractory breast cancer compared to other drugs in development. Seragon's most advanced leads induce tumor regressions in both tamoxifen sensitive and tamoxifen resistant tumor models in vivo. Based on these results and others, the company is currently advancing multiple, distinct lead SERD chemical scaffolds toward clinical development. Seragon's SERDs are initially being developed for the treatment of women with late-stage, progressive metastatic disease.

Current Team (1)

Update

Funding Rounds (1) - $30M

Update

Offices/Locations (1)

Update
  • Office

    12780 El Camino Real

    Suite #302

    San Diego, CA 92130

    USA

Images (1)

Update
  • 2eaacfa94a2718e213832368e5f6b938